On May 28, 2026, the 7th CGCS 2026 International Summit on Cell and Gene Therapy in China and its supporting exhibition successfully concluded in Suzhou. This summit is hosted by the CGCS organizing committee, and the conference relies on authoritative expert evaluations and an industry wide online public selection system to officially release the results of the "CGT Best CRO Partner Qimingxing Award".

Shandong Xinbo Pharmaceutical Research Co., Ltd. is deeply engaged in the field of non clinical CRO. With its technology platform and service capabilities, it has won the "Best CRO Partner Qimingxing Award in CGT Field" and has been recognized by the industry.

Authoritative summit recognition, strength wins honors

This year's CGCS 2026 was grandly held in Suzhou, which is an influential industry event in the field of CGT. It gathers global innovation forces, focuses on cutting-edge technologies in cell and gene therapy, clinical translation, and industrial development. It is a core platform for communication and cooperation between domestic and foreign CGT enterprises, research institutions, and industry chain partners.

The highly anticipated CGCS Awards 2026, initiated by the CGCS organizing committee, aims to recognize outstanding enterprises in the field of CGT that have outstanding technological innovation, leading service capabilities, and made outstanding contributions to industry development. The selection process is strict. Shandong Xinbo has won this honor, reflecting the company's industry attention in CRO services in the CGT field.

Deeply cultivate CGT safety evaluation and build a solid foundation for innovative research and development

As a national high-tech enterprise and Shandong Provincial Enterprise Technology Center, Shandong Xinbo has been deeply involved in the field of preclinical safety evaluation of drugs for many years. With the concept of "striving for excellence", it focuses on cutting-edge fields such as CGT and has built a full process preclinical safety evaluation service system covering cell therapy, gene therapy, therapeutic vaccines and other products.

Since its establishment in 2010, the company has provided over 12000 services to more than 630 pharmaceutical companies and research institutes at home and abroad, completed nearly 550 preclinical evaluations of innovative drugs, and accumulated rich project experience in the field of CGT drug evaluation. It has successfully assisted in the smooth promotion of multiple CGT pipelines and injected strong impetus into the high-quality development of China's CGT industry.